Unraveling resistance to immune checkpoint inhibitors in HNSCC: from mechanisms to combination therapies

Abstract

Head and neck squamous cell carcinoma (HNSCC), which arises from the mucosal linings of the oral cavity, pharynx, and larynx, represents the most prevalent head and neck malignancy. This cancer is notable for its elevated incidence and substantial mortality. The intricate anatomy of the region contributes to marked tumor heterogeneity, rendering the pursuit of effective therapeutic regimens a crucial aspect of enhancing clinical outcomes. Recently, the advent of immune checkpoint blockade, particularly agents targeting programmed death-1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4, has introduced significant advancements within the oncological landscape, including for HNSCC. The introduction of immune checkpoint inhibitors, specifically the PD-1 blockers pembrolizumab and nivolumab, has established a new therapeutic standard for recurrent/metastatic HNSCC (R/M HNSCC). However, the clinical benefit is not universal, as a primary challenge remains the high incidence of treatment resistance. Consequently, a majority of patients (approximately 60%-70%) with R/M HNSCC derive minimal or no benefit from this form of immunotherapy, highlighting the critical need to understand the underlying resistance mechanisms. This review comprehensively discusses the types of immunotherapy resistance in HNSCC and the underlying mechanisms contributing to resistance. Furthermore, it reviews current strategies to overcome immunotherapy resistance, providing new perspectives for improving therapeutic efficacy in HNSCC.

Keywords

R/M HNSCC / immunotherapy / therapy resistance / PD-1 / therapeutic strategies

References

[1] Bhatia A.Treating head and neck cancer in the age of immunotherapy: a 2023 update.Drugs2023;83:217-48

[2] Bray F,Sung H.Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA Cancer J Clin2024;74:229-63

[3] Elmusrati A,Wang C.Tumor microenvironment and immune evasion in head and neck squamous cell carcinoma.Int J Oral Sci2021;13:131 PMCID:PMC8329257

[4] Johnson DE,Leemans CR,Bauman JE.Head and neck squamous cell carcinoma.Nat Rev Dis Primers2020;6:92 PMCID:PMC7944998

[5] Harrington K,Soulières D.Pembrolizumab versus methotrexate, docetaxel, or cetuximab in recurrent or metastatic head and neck squamous cell carcinoma (KEYNOTE-040): subgroup analysis by pattern of disease recurrence.Oral Oncol2023;147:106587

[6] Caudell JJ,Maghami E.NCCN Guidelines® Insights: head and neck cancers, version 1.2022.J Natl Compr Canc Netw2022;20:224-34

[7] Keam B,Kim HR.Pan-Asian adaptation of the EHNS-ESMO-ESTRO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with squamous cell carcinoma of the head and neck.ESMO Open2021;6:100309 PMCID:PMC8710460

[8] Chinese Society of Clinical Oncology (CSCO) diagnosis and treatment guidelines for head and neck cancer 2018 (English version).Chin J Cancer Res2019;31:84-98 PMCID:PMC6433588

[9] Gong J,Reddi S.Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations.J Immunother Cancer2018;6:8 PMCID:PMC5778665

[10] Seiwert TY,Mehra R.Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial.Lancet Oncol2016;17:956-65

[11] Ferris RL,Fayette J.Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression.Oral Oncol2018;81:45-51 PMCID:PMC6563923

[12] Bauml J,Pfister DG.Pembrolizumab for platinum- and cetuximab-refractory head and neck cancer: results from a single-arm, phase II study.J Clin Oncol2017;35:1542-9 PMCID:PMC5946724

[13] Burtness B,Greil R.Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.Lancet2019;394:1915-28

[14] Haddad RI,Tahara M.Nivolumab plus ipilimumab versus EXTREME regimen as first-line treatment for recurrent/metastatic squamous cell carcinoma of the head and neck: the final results of CheckMate 651.J Clin Oncol2023;41:2166-80 PMCID:PMC10115555

[15] Machiels J,Licitra L.Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial.Lancet Oncol2024;25:572-87

[16] Harrington KJ,Gillison M.Efficacy and safety of nivolumab plus ipilimumab vs nivolumab alone for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck: the phase 2 CheckMate 714 randomized clinical trial.JAMA Oncol2023;9:779-89 PMCID:PMC10080406

[17] Psyrri A,Harrington K.Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III study.Ann Oncol2023;34:262-74

[18] Harrington KJ,Blumenschein G Jr.Nivolumab versus standard, single-agent therapy of investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial.Lancet Oncol2017;18:1104-15 PMCID:PMC6461049

[19] Cohen EEW, Soulières D, Le Tourneau C, et al.; KEYNOTE-040 investigators. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study.Lancet2019;393:156-67

[20] Cohen EEW,Bifulco CB.The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC).J Immunother Cancer2019;7:184 PMCID:PMC6632213

[21] Huang Z,Ding S.Prognostic role of programmed cell death ligand-1 expression in head and neck cancer treated with programmed cell death protein-1/programmed cell death ligand-1 inhibitors: a meta-analysis based on clinical trials.J Cancer Res Ther2021;17:676-87

[22] Emancipator K,Aurora-Garg D.Comparing programmed death ligand 1 scores for predicting pembrolizumab efficacy in head and neck cancer.Mod Pathol2021;34:532-41

[23] Ferris RL,Fayette J.Nivolumab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: efficacy and safety in CheckMate 141 by prior cetuximab use.Clin Cancer Res2019;25:5221-30 PMCID:PMC7721346

[24] Yilmaz E,Bauman JE.Immunotherapy and biomarker testing in recurrent and metastatic head and neck cancers: ASCO Guideline.J Clin Oncol2023;41:1132-46

[25] Marabelle A,Lopez J.Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study.Lancet Oncol2020;21:1353-65

[26] Haddad RI,Chow LQM.Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinoma.J Immunother Cancer2022;10:e003026 PMCID:PMC8883256

[27] Stein AP,Kraninger JL.Prevalence of human papillomavirus in oropharyngeal cancer: a systematic review.Cancer J2015;21:138-46 PMCID:PMC4459520

[28] Argiris A,Ghebremichael M.Prognostic significance of human papillomavirus in recurrent or metastatic head and neck cancer: an analysis of Eastern Cooperative Oncology Group trials.Ann Oncol2014;25:1410-6 PMCID:PMC4071756

[29] Fakhry C,Nguyen-Tan PF.Human papillomavirus and overall survival after progression of oropharyngeal squamous cell carcinoma.J Clin Oncol2014;32:3365-73 PMCID:PMC4195851

[30] Sahovaler A,Mendez A.Survival outcomes in human papillomavirus–associated nonoropharyngeal squamous cell carcinomas: a systematic review and meta-analysis.JAMA Otolaryngol Head Neck Surg2020;146:1158-66 PMCID:PMC7563675

[31] Wang H,Wang B.Role of human papillomavirus in laryngeal squamous cell carcinoma: a meta-analysis of cohort study.Cancer Med2020;9:204-14 PMCID:PMC6943161

[32] Nguyen N, Bellile E, Thomas D, et al.; Head and Neck SPORE Program Investigators. Tumor infiltrating lymphocytes and survival in patients with head and neck squamous cell carcinoma.Head Neck2016;38:1074-84 PMCID:PMC4900934

[33] Mandal R,Desrichard A.The head and neck cancer immune landscape and its immunotherapeutic implications.JCI Insight2016;1:e89829 PMCID:PMC5070962

[34] Kim TK,Chen L.Defining and understanding adaptive resistance in cancer immunotherapy.Trends Immunol2018;39:624-31 PMCID:PMC6066429

[35] Sharma P,Wargo JA.Primary, adaptive, and acquired resistance to cancer immunotherapy.Cell2017;168:707-23 PMCID:PMC5391692

[36] Dunn GP,Schreiber RD.The three Es of cancer immunoediting.Annu Rev Immunol2004;22:329-60

[37] Seliger B.Molecular mechanisms of MHC class I abnormalities and APM components in human tumors.Cancer Immunol Immunother2008;57:1719-26 PMCID:PMC11030176

[38] Zandberg DP,Jimeno A.Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: results from a single-arm, phase II study in patients with ≥ 25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy.Eur J Cancer2019;107:142-52

[39] Lyford-Pike S,Young GD.Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma.Cancer Res2013;73:1733-41 PMCID:PMC3602406

[40] Wilson EB.The role of IL-10 in regulating immunity to persistent viral infections.Curr Top Microbiol Immunol2011;350:39-65 PMCID:PMC3492216

[41] Koyama S,Li YY.Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints.Nat Commun2016;7:10501 PMCID:PMC4757784

[42] Gabrilovich DI,Bronte V.Coordinated regulation of myeloid cells by tumours.Nat Rev Immunol2012;12:253-68 PMCID:PMC3587148

[43] Andrews LP,Karapetyan L,Workman CJ.Molecular pathways and mechanisms of LAG3 in cancer therapy.Clin Cancer Res2022;28:5030-9 PMCID:PMC9669281

[44] Park JS,Wu M.Targeting PD-L2–RGMb overcomes microbiome-related immunotherapy resistance.Nature2023;617:377-85 PMCID:PMC10219577

[45] Zhao Y,Lin CH.PD-L1:CD80 cis-heterodimer triggers the co-stimulatory receptor CD28 while repressing the inhibitory PD-1 and CTLA-4 pathways.Immunity2019;51:1059-73.e9 PMCID:PMC6935268

[46] Ren D,Yu B.Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy.Mol Cancer2020;19:19 PMCID:PMC6993488

[47] Herbst RS,Kowanetz M.Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.Nature2014;515:563-7 PMCID:PMC4836193

[48] Ribas A.Cancer immunotherapy using checkpoint blockade.Science2018;359:1350-5 PMCID:PMC7391259

[49] Joller N,Kuchroo VK.LAG-3, TIM-3, and TIGIT: distinct functions in immune regulation.Immunity2024;57:206-22 PMCID:PMC10919259

[50] Navasardyan I.Regulation of T cells in cancer by nitric oxide.Cells2021;10:2655 PMCID:PMC8534057

[51] Basheeruddin M.Hypoxia-inducible factor 1-alpha (HIF-1α) and cancer: mechanisms of tumor hypoxia and therapeutic targeting.Cureus2024;16:e70700 PMCID:PMC11529905

[52] Gabrilovich DI,Girgis KR.Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells.Nat Med1996;2:1096-103

[53] Johnson DB,Moslehi JJ.Immune-checkpoint inhibitors: long-term implications of toxicity.Nat Rev Clin Oncol2022;19:254-67 PMCID:PMC8790946

[54] Lui VW,Li H.Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers.Cancer Discov2013;3:761-9 PMCID:PMC3710532

[55] Mcgranahan N,Rosenthal R.Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade.Science2016;351:1463-9 PMCID:PMC4984254

[56] Bakhoum SF,Laughney AM.Chromosomal instability drives metastasis through a cytosolic DNA response.Nature2018;553:467-72 PMCID:PMC5785464

[57] van Dorp J, van der Heijden MS. The bladder cancer immune micro-environment in the context of response to immune checkpoint inhibition.Front Immunol2023;14:1235884 PMCID:PMC10505825

[58] Cao Y,Chen Q,Wang Z.Multifunctional ICG-SB@Lip-ZA nanosystem focuses on remodeling the inflammatory-immunosuppressive microenvironment after photothermal therapy to potentiate cancer photothermal immunotherapy.Adv Healthc Mater2025;14:e2402211

[59] Yan R,Gegenhuber B.T cell-mediated development of stromal fibroblasts with an immune-enhancing chemokine profile.Cancer Immunol Res2023;11:1044-54 PMCID:PMC10700667

[60] Liu Z,Zhang Y.Spatial transcriptomics reveals that metabolic characteristics define the tumor immunosuppression microenvironment via iCAF transformation in oral squamous cell carcinoma.Int J Oral Sci2024;16:267 PMCID:PMC10824761

[61] Dai E,Li Y,Li Y.Lactate and lactylation: behind the development of tumors.Cancer Lett2024;591:216896

[62] Shi H,Chi H.Immunometabolism of CD8⁺ T cell differentiation in cancer.Trends Cancer2024;10:610-26 PMCID:PMC11342304

[63] Imani S,Roozitalab G.Reprogramming the breast tumor immune microenvironment: cold-to-hot transition for enhanced immunotherapy.J Exp Clin Cancer Res2025;44:131 PMCID:PMC12032666

[64] Wu W,Sun H.Glycolysis induces abnormal transcription through histone lactylation in T-cell acute lymphoblastic leukemia.Genomics Proteomics Bioinformatics2025;23:qzaf029 PMCID:PMC12402983

[65] Wang S,Wu Q.Lactate reprograms glioblastoma immunity through CBX3-regulated histone lactylation.J Clin Invest2024;134:e176851 PMCID:PMC11563687

[66] Pich-Bavastro C,Di Domizio J,Gilliet M.Activin A-mediated polarization of cancer-associated fibroblasts and macrophages confers resistance to checkpoint immunotherapy in skin cancer.Clin Cancer Res2023;29:3498-513 PMCID:PMC10472111

[67] Yan J,Patel AJ.Tumor-intrinsic PRC2 inactivation drives a context-dependent immune-desert microenvironment and is sensitized by immunogenic viruses.J Clin Invest2022;132:e153437 PMCID:PMC9433107

[68] Zhu Z,Song W.A novel cuproptosis-related molecular pattern and its tumor microenvironment characterization in colorectal cancer.Front Immunol2022;13:940774 PMCID:PMC9561547

[69] Zheng G,Yang Z.Immune desert in MMR-deficient tumors predicts poor responsiveness of immune checkpoint inhibition.Front Immunol2023;14:1142862 PMCID:PMC10175608

[70] Vredevoogd DW.Heterogeneity in functional genetic screens: friend or foe?.Front Immunol2023;14:1162706 PMCID:PMC10312307

[71] Lauss M,Borch TH.Molecular patterns of resistance to immune checkpoint blockade in melanoma.Nat Commun2024;15:3075 PMCID:PMC11004175

[72] Mancini C,Pranzini E.Metabolic challengers selecting tumor-persistent cells.Trends Endocrinol Metab2024;35:263-76

[73] Abdulrahman Z,Mcguire D,van Poelgeest MIE.Single-cell spatial transcriptomics unravels cell states and ecosystems associated with clinical response to immunotherapy.J Immunother Cancer2025;13:e011308 PMCID:PMC11907085

[74] van Weverwijk A, de Visser KE. Mechanisms driving the immunoregulatory function of cancer cells.Nat Rev Cancer2023;23:193-215

[75] Aldea M,Marabelle A,Barlesi F.Overcoming resistance to tumor-targeted and immune-targeted therapies.Cancer Discov2021;11:874-99

[76] Murciano-Goroff YR,Wolchok JD.The future of cancer immunotherapy: microenvironment-targeting combinations.Cell Res2020;30:507-19 PMCID:PMC7264181

[77] Brooks ED.Time to abandon single-site irradiation for inducing abscopal effects.Nat Rev Clin Oncol2019;16:123-35

[78] Galluzzi L,Warren S.Consensus guidelines for the definition, detection and interpretation of immunogenic cell death.J Immunother Cancer2020;8:e000337 PMCID:PMC7064135

[79] Leduc C,Louvet E.TPF induction chemotherapy increases PD-L1 expression in tumour cells and immune cells in head and neck squamous cell carcinoma.ESMO Open2018;3:e000257 PMCID:PMC5761289

[80] Rottenberg S,Perego P.The rediscovery of platinum-based cancer therapy.Nat Rev Cancer2021;21:37-50

[81] Garg AD,Rufo N.Trial watch: immunogenic cell death induction by anticancer chemotherapeutics.OncoImmunology2017;6:e1386829 PMCID:PMC5706600

[82] Wang J,Lv J.A tumor-specific ROS self-supply enhanced cascade-responsive prodrug activation nanosystem for amplified chemotherapy against multidrug-resistant tumors.Acta Biomaterialia2023;164:522-37

[83] Fu J,Yang Y.Activatable nanomedicine for overcoming hypoxia-induced resistance to chemotherapy and inhibiting tumor growth by inducing collaborative apoptosis and ferroptosis in solid tumors.Biomaterials2021;268:120537

[84] Fucikova J,Kasikova L.Detection of immunogenic cell death and its relevance for cancer therapy.Cell Death Dis2020;11:1013 PMCID:PMC7691519

[85] Long Y,Chen J.GPR162 activates STING dependent DNA damage pathway as a novel tumor suppressor and radiation sensitizer.Sig Transduct Target Ther2023;8:1224 PMCID:PMC9892510

[86] Du S,Yang P.Radiation therapy promotes hepatocellular carcinoma immune cloaking via PD-L1 upregulation induced by cGAS-STING activation.Int J Radiat Oncol Biol Phys2022;112:1243-55

[87] Jin WJ,Hyun M.ATM inhibition augments type I interferon response and antitumor T-cell immunity when combined with radiation therapy in murine tumor models.J Immunother Cancer2023;11:e007474 PMCID:PMC10510866

[88] Seyedin SN,Pham V.Combination therapy with radiation and PARP inhibition enhances responsiveness to anti-PD-1 therapy in colorectal tumor models.Int J Radiat Oncol Biol Phys2020;108:81-92 PMCID:PMC7416439

[89] Liu S,Hu S.Radiotherapy remodels the tumor microenvironment for enhancing immunotherapeutic sensitivity.Cell Death Dis2023;14:679 PMCID:PMC10575861

[90] Wang Y,Yuan H.The reciprocity between radiotherapy and cancer immunotherapy.Clin Cancer Res2019;25:1709-17 PMCID:PMC6420874

[91] Weiss J,Deal AM.Concurrent definitive immunoradiotherapy for patients with stage III–IV head and neck cancer and cisplatin contraindication.Clin Cancer Res2020;26:4260-7 PMCID:PMC7968114

[92] Lee NY,Psyrri A.Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.Lancet Oncol2021;22:450-62

[93] Ferris R,Even C.Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study.Ann Oncol2020;31:942-50

[94] Ferris RL,Chiosea SI.Neoadjuvant nivolumab alone or in combination with relatlimab or ipilimumab in resectable head and neck squamous cell carcinoma (HNSCC).J Clin Oncol2023;41:6018

[95] Perez-Santos M,Villafaña-Diaz L.Approaches for development of LAG-3 inhibitors and the promise they hold as anticancer agents.Expert Opin Drug Discov2022;17:1341-55

[96] Cho BC,Zhu X.A phase 1 study of fianlimab (anti–LAG-3) in combination with cemiplimab (anti–PD-1) in patients with advanced HNSCC.J Clin Oncol2024;42:6038

[97] Patel MR,Winer I.Ezabenlimab (BI 754091), an anti-PD-1 antibody, in patients with advanced solid tumours.Cancer Immunol Immunother2024;73:89 PMCID:PMC10981579

[98] Yap TA,Wong DJ.A phase 1 first-in-human study of FS118, a tetravalent bispecific antibody targeting LAG-3 and PD-L1 in patients with advanced cancer and PD-L1 resistance.Clin Cancer Res2023;29:888-98

[99] Giri VK,Zaemes J.The emerging role of lymphocyte-activation gene 3 targeting in the treatment of solid malignancies.Cancer2025;131:e35892

[100] Obara G,Loo D.Phase 2 trial of enoblituzumab plus retifanlimab or tebotelimab in first-line treatment of patients (pts) with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN).J Clin Oncol2022;40:TPS6102

[101] Forster M,Pousa AL.Eftilagimod alpha (soluble LAG3 protein) combined with pembrolizumab as second-line therapy for patients with metastatic head and neck squamous cell carcinoma.Clin Cancer Res2024;30:3726-34

[102] Curigliano G,Mach N.Phase I/Ib clinical trial of sabatolimab, an anti–TIM-3 antibody, alone and in combination with spartalizumab, an anti–PD-1 antibody, in advanced solid tumors.Clin Cancer Res2021;27:3620-9

[103] Sun M,Wang W.Advancements in the research of immune checkpoint inhibitors for the treatment of advanced esophageal squamous cell carcinoma.Am J Cancer Res2024;14:1981-98 PMCID:PMC11162652

[104] Malhotra J,Amini A.Novel immunotherapeutics for the treatment of non-small cell lung cancer (NSCLC) resistant to PD-1/PD-L1 inhibitors.Cancers2024;16:3603 PMCID:PMC11545025

[105] Cohen E,Harrington K.927TiP SKYSCRAPER-09: a phase II, randomised, double-blinded study of atezolizumab (Atezo) + tiragolumab (Tira) and atezo + placebo as first-line (1L) therapy for recurrent/metastatic (R/M) PD-L1+ squamous cell carcinoma of the head and neck (SCCHN).Ann Oncol2021;32:S814-5

[106] Mettu NB,Bendell JC.A phase 1a/b open-label, dose-escalation study of etigilimab alone or in combination with nivolumab in patients with locally advanced or metastatic solid tumors.Clin Cancer Res2022;28:882-92

[107] Cohen EEW,Wong DJ.Intralesional SD-101 in combination with pembrolizumab in anti-PD-1 treatment-naïve head and neck squamous cell carcinoma: results from a multicenter, phase II trial.Clin Cancer Res2022;28:1157-66 PMCID:PMC9365346

[108] Hansen AR,Hong MH.INDUCE-3: a randomized, double-blind study of GSK3359609 (GSK609), an inducible T-cell co-stimulatory (ICOS) agonist antibody, plus pembrolizumab (PE) versus placebo (PL) plus PE for first-line treatment of PD-L1-positive recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).J Clin Oncol2020;38:TPS6591

[109] Grosso JF,Getnet D.Functionally distinct LAG-3 and PD-1 subsets on activated and chronically stimulated CD8 T cells.J Immunol2009;182:6659-69 PMCID:PMC3082361

[110] Woo S,Goldberg MV.Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape.Cancer Res2012;72:917-27 PMCID:PMC3288154

[111] Triebel F,Baixeras E.LAG-3, a novel lymphocyte activation gene closely related to CD4.J Exp Med1990;171:1393-405 PMCID:PMC2187904

[112] Grebinoski S,Cillo AR.Autoreactive CD8⁺ T cells are restrained by an exhaustion-like program that is maintained by LAG3.Nat Immunol2022;23:868-77 PMCID:PMC9179227

[113] Huang CT,Flies D.Role of LAG-3 in regulatory T cells.Immunity2004;21:503-13

[114] Tawbi HA, Schadendorf D, Lipson EJ, et al.; RELATIVITY-047 Investigators. Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma.N Engl J Med2022;386:24-34 PMCID:PMC9844513

[115] Monney L,Gaglia JL.Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease.Nature2002;415:536-41

[116] Anderson AC,Bregoli L.Promotion of tissue inflammation by the immune receptor Tim-3 expressed on innate immune cells.Science2007;318:1141-3

[117] Phong BL,Sumpter TL.Tim-3 enhances FcεRI-proximal signaling to modulate mast cell activation.J Exp Med2015;212:2289-304 PMCID:PMC4689164

[118] Ndhlovu LC,Barbour JD.Tim-3 marks human natural killer cell maturation and suppresses cell-mediated cytotoxicity.Blood2012;119:3734-43 PMCID:PMC3335380

[119] Sakuishi K,Sullivan JM,Kuchroo VK.Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity.J Exp Med2010;207:2187-94 PMCID:PMC2947065

[120] Jin HT,Tan WG.Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection.Proc Natl Acad Sci U S A2010;107:14733-8 PMCID:PMC2930455

[121] Brunner AM,Porkka K.Efficacy and safety of sabatolimab (MBG453) in combination with hypomethylating agents (HMAs) in patients (Pts) with very high/high-risk myelodysplastic syndrome (vHR/HR-MDS) and acute myeloid leukemia (AML): final analysis from a phase Ib study.Blood2021;138:244

[122] Falchook GS,Davar D.Phase 1 trial of TIM-3 inhibitor cobolimab monotherapy and in combination with PD-1 inhibitors nivolumab or dostarlimab (AMBER).J Clin Oncol2022;40:2504

[123] Yu X,Gonzalez LC.The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells.Nat Immunol2009;10:48-57

[124] Anderson A,Kuchroo V.Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation.Immunity2016;44:989-1004 PMCID:PMC4942846

[125] Yamada T,Takasuga S.TIGIT mediates activation-induced cell death of ILC2s during chronic airway allergy.J Exp Med2023;220 PMCID:PMC10098142

[126] Brauneck F,Witt M.TIGIT blockade repolarizes AML-associated TIGIT⁺ M2 macrophages to an M1 phenotype and increases CD47-mediated phagocytosis.J Immunother Cancer2022;10:e004794 PMCID:PMC9791419

[127] Kurtulus S,Ngiow SF.TIGIT predominantly regulates the immune response via regulatory T cells.J Clin Invest2024;134:e183278 PMCID:PMC11213499

[128] Cho BC,Hussein M.Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study.Lancet Oncol2022;23:781-92

[129] Chu X,Wang Z,Zhou R.Co-inhibition of TIGIT and PD-1/PD-L1 in cancer immunotherapy: mechanisms and clinical trials.Mol Cancer2023;22:1800 PMCID:PMC10249258

[130] Chapoval AI,Lau JS.B7-H3: a costimulatory molecule for T cell activation and IFN-γ production.Nat Immunol2001;2:269-74

[131] Suh WK,Okada H.The B7 family member B7-H3 preferentially down-regulates T helper type 1-mediated immune responses.Nat Immunol2003;4:899-906

[132] Chen J,Ku K.Glycoprotein B7-H3 overexpression and aberrant glycosylation in oral cancer and immune response.Proc Natl Acad Sci U S A2015;112:13057-62 PMCID:PMC4620862

[133] Elbers JBW,Tesseslaar MET.Immuno-radiotherapy with cetuximab and avelumab for advanced stage head and neck squamous cell carcinoma: results from a phase-I trial.Radiother Oncol2020;142:79-84

[134] Amatore F,Olive D.Inducible Co-Stimulator (ICOS) as a potential therapeutic target for anti-cancer therapy.Expert Opin Ther Targets2018;22:343-51

[135] Solinas C,Willard-Gallo K.The rationale behind targeting the ICOS-ICOS ligand costimulatory pathway in cancer immunotherapy.ESMO Open2020;5:e000544 PMCID:PMC7003380

[136] Dongye Z,Wu Y.Toll-like receptor 9 agonists and combination therapies: strategies to modulate the tumour immune microenvironment for systemic anti-tumour immunity.Br J Cancer2022;127:1584-94 PMCID:PMC9333350

[137] Ribas A,Kirkwood JM.Overcoming PD-1 blockade resistance with CpG-A Toll-like receptor 9 agonist vidutolimod in patients with metastatic melanoma.Cancer Discov2021;11:2998-3007 PMCID:PMC8799774

[138] Cohen EEW,Wong DJL.Phase 1b/2, open label, multicenter study of intratumoral SD-101 in combination with pembrolizumab in anti-PD-1 treatment naïve patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).J Clin Oncol2019;37:6039

[139] Chen N,Zhan J.Upregulation of PD-L1 by EGFR activation mediates the immune escape in EGFR-driven NSCLC: implication for optional immune targeted therapy for NSCLC patients with EGFR mutation.J Thorac Oncol2015;10:910-23

[140] Sacco AG,Worden FP.Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial.Lancet Oncol2021;22:883-92 PMCID:PMC12140401

[141] Gulati S,Riaz MK.Durvalumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, nonrandomized, phase II clinical trial.Clin Cancer Res2023;29:1906-15 PMCID:PMC10192200

[142] Wang X,Slebos RJC.Clinical significance of peripheral T-cell repertoire in head and neck squamous cell carcinoma treated with cetuximab and nivolumab.Cancer Immunol Immunother2025;74:142 PMCID:PMC11890688

[143] Lee CH,Rasco D.Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study.Lancet Oncol2021;22:946-58 PMCID:PMC8316679

[144] Siu LL,Cohen EEW.Phase III LEAP-010 study: first-line pembrolizumab with or without lenvatinib in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).J Clin Oncol2020;38:TPS6589

[145] Gangadhar TC,Smith DC.Preliminary results from a Phase I/II study of epacadostat (incb024360) in combination with pembrolizumab in patients with selected advanced cancers.J Immunother Cancer2015;3:O7

[146] dos Santos LV, Abrahão CM, William WN. Overcoming resistance to immune checkpoint inhibitors in head and neck squamous cell carcinomas.Front Oncol2021;11:596290 PMCID:PMC7973277

[147] Zhang S,Nie D.Efficacy of cetuximab plus PD-1 inhibitor differs by HPV status in head and neck squamous cell carcinoma: a systematic review and meta-analysis.J Immunother Cancer2022;10:e005158 PMCID:PMC9577924

[148] Taylor MH,Brose MS.A phase 1b/2 trial of lenvatinib plus pembrolizumab in patients with squamous cell carcinoma of the head and neck.J Clin Oncol2018;36:6016

[149] Licitra L,Harrington K.Pembrolizumab with or without lenvatinib as first-line therapy for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): phase 3 LEAP-010 study.Int J Radiat Oncol Biol Phys2024;118:e2-3

[150] Adkins D,Liu J.Ramucirumab in combination with pembrolizumab for recurrent or metastatic head and neck squamous cell carcinoma: a single-centre, phase 1/2 trial.Lancet Oncol2024;25:888-900 PMCID:PMC12571033

[151] Saba NF,Ekpenyong A.Pembrolizumab and cabozantinib in recurrent metastatic head and neck squamous cell carcinoma: a phase 2 trial.Nat Med2023;29:880-7 PMCID:PMC10205145

[152] Economopoulou P,Strati A.Prognostic impact of indoleamine 2,3-dioxygenase 1 (IDO1) mRNA expression on circulating tumour cells of patients with head and neck squamous cell carcinoma.ESMO Open2020;5:e000646 PMCID:PMC7232623

[153] Munn DH.IDO in the tumor microenvironment: inflammation, counter-regulation, and tolerance.Trends Immunol2016;37:193-207 PMCID:PMC4916957

[154] Munn DH.Indoleamine 2,3-dioxygenase and tumor-induced tolerance.J Clin Invest2007;117:1147-54 PMCID:PMC1857253

[155] Holmgaard R,Li Y.Tumor-expressed IDO recruits and activates MDSCs in a treg-dependent manner.Cell Rep2015;13:412-24 PMCID:PMC5013825

[156] Hamid O,Spira AI.Epacadostat plus pembrolizumab in patients with SCCHN: Preliminary phase I/II results from ECHO-202/KEYNOTE-037.J Clin Oncol2017;35:6010

[157] Long GV,Hamid O.Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study.Lancet Oncol2019;20:1083-97

[158] Wang X,Wang Y.DNA sensing via the cGAS/STING pathway activates the immunoproteasome and adaptive T-cell immunity.EMBO J2023;42:e110597 PMCID:PMC10106989

[159] Powles T, Valderrama BP, Gupta S, et al.; EV-302 Trial Investigators. Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer.N Engl J Med2024;390:875-88 PMCID:PMC12361773

[160] Raja J,Gettinger SN,Kim HS.Oncolytic virus immunotherapy: future prospects for oncology.J Immunother Cancer2018;6:140 PMCID:PMC6280382

[161] Wong MKK,Robert C.Efficacy and safety of RP1 combined with nivolumab in patients with anti–PD-1–failed melanoma from the IGNYTE clinical trial.J Clin Oncol2024;42:9517

[162] Dong H,Yang C.Combination therapy with oncolytic viruses and immune checkpoint inhibitors in head and neck squamous cell carcinomas: an approach of complementary advantages.Cancer Cell Int2023;23:2846 PMCID:PMC9814316

[163] Wang Z,Li Z.Clinical advances and future directions of oncolytic virotherapy for head and neck cancer.Cancers2023;15:5291 PMCID:PMC10650136

[164] Jain RK.Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy.Science2005;307:58-62

[165] Guo C,Wang Y,Gong Q.Nano drug delivery systems for advanced immune checkpoint blockade therapy.Theranostics2025;15:5440-80 PMCID:PMC12036873

[166] Zhang Z,Du J.Redox-responsive polymer micelles co-encapsulating immune checkpoint inhibitors and chemotherapeutic agents for glioblastoma therapy.Nat Commun2024;15:44963 PMCID:PMC10847518

[167] Qian M,Guo W.A biodegradable nanosuspension locally used for inhibiting postoperative recurrence and brain metastasis of breast cancer.Nano Lett2024;24:3165-75

[168] Tang B,Wang Y.Targeted xCT-mediated ferroptosis and protumoral polarization of macrophages is effective against HCC and enhances the efficacy of the anti-PD-1/L1 response.Adv Sci2023;10:e2203973 PMCID:PMC9839855

[169] Fu S,Shen L.Cu₂WS₄-PEG nanozyme as multifunctional sensitizers for enhancing immuno-radiotherapy by inducing ferroptosis.Small2024;20:e2309537

[170] Uppaluri R, Haddad RI, Tao Y, et al.; KEYNOTE-689 Investigators. Neoadjuvant and adjuvant pembrolizumab in locally advanced head and neck cancer.N Engl J Med2025;393:37-50

[171] Orland MD,Yilmaz E.Immunotherapy for head and neck squamous cell carcinoma: present and future approaches and challenges.JCO Oncol Pract2024;20:1588-95

[172] De Felice F, Cattaneo CG, Franco P. Radiotherapy and systemic therapies: focus on head and neck cancer.Cancers2023;15:4232 PMCID:PMC10486947

[173] Liu C,Liu X.Evaluating the efficacy and safety of different neoadjuvant immunotherapy combinations in locally advanced HNSCC: a systematic review and meta-analysis.Front Immunol2024;15:1467306 PMCID:PMC11390592

[174] Yu X,Li Z,Sun S.Influence of microbiota on tumor immunotherapy.Int J Biol Sci2024;20:2264-94 PMCID:PMC11008264

[175] Elkrief A,Maleki Vareki S,Castagner B.The gut microbiome as a target in cancer immunotherapy: opportunities and challenges for drug development.Nat Rev Drug Discov2025;24:685-704

[176] Hadjigeorgiou AG,Mishra AK.Mathematical modeling and association analysis decipher the impact of the gut microbiome on cancer immunotherapy.Cancer Res2025;85:3139-55 PMCID:PMC12355177

[177] Xia L,Wang Y.The gut microbiota improves the efficacy of immune-checkpoint inhibitor immunotherapy against tumors: from association to cause and effect.Cancer Lett2024;598:217123

[178] Zheng Q,Lian H.Gut microbial signatures associated with clinical remission in inflammatory bowel disease treated with biologics: a comprehensive multi-cohort analysis.United European Gastroenterol J2025;13:1263-77 PMCID:PMC12463721

[179] He Y,Asokan S,Elinav E.Microbiome modulation of antigen presentation in tolerance and inflammation.Curr Opin Immunol2024;91:102471

[180] Marin D,Basar R.Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1/2 trial.Nat Med2024;30:772-84 PMCID:PMC10957466

[181] Hosseinalizadeh H,Mirzaei H,Tian L.Emerging combined CAR-NK cell therapies in cancer treatment: finding a dancing partner.Mol Ther2025;33:2406-25 PMCID:PMC12172187

[182] Lamers-Kok N,Georgoudaki AM.Natural killer cells in clinical development as non-engineered, engineered, and combination therapies.J Hematol Oncol2022;15:164 PMCID:PMC9644572

[183] Zandberg D,Laux D.71P A phase II study of ADU-S100 in combination with pembrolizumab in adult patients with PD-L1+ recurrent or metastatic HNSCC: preliminary safety, efficacy and PK/PD results.Ann Oncol2020;31:S1446-7

[184] Masarwy R,Stotsky-Oterin L.Targeted CRISPR/Cas9 lipid nanoparticles elicits therapeutic genome editing in head and neck cancer.Adv Sci2025;12:e2411032 PMCID:PMC11831472

[185] Hellmann MD,Opyrchal M.Entinostat plus pembrolizumab in patients with metastatic NSCLC previously treated with anti–PD-(L)1 therapy.Clin Cancer Res2021;27:1019-28 PMCID:PMC7887114

[186] Li Y,Zhou L.DNMT1 inhibition reprograms T cells to NK-like cells with potent antitumor activity.Sci Immunol2025;10:eadm8251

[187] Wang D,Sui L,Xu S.Natural killer cells in cancer immunotherapy.MedComm2024;5:e626 PMCID:PMC11179524